Diamyd Medical Management
Management criteria checks 3/4
Diamyd Medical's CEO is Ulf Hannelius, appointed in Apr 2016, has a tenure of 8.83 years. total yearly compensation is SEK3.43M, comprised of 70.4% salary and 29.6% bonuses, including company stock and options. directly owns 0.27% of the company’s shares, worth SEK4.50M. The average tenure of the management team and the board of directors is 5 years and 13.1 years respectively.
Key information
Ulf Hannelius
Chief executive officer
SEK 3.4m
Total compensation
CEO salary percentage | 70.4% |
CEO tenure | 8.8yrs |
CEO ownership | 0.3% |
Management average tenure | 5yrs |
Board average tenure | 13.1yrs |
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Nov 30 2024 | n/a | n/a | -SEK 155m |
Aug 31 2024 | SEK 3m | SEK 2m | -SEK 152m |
May 31 2024 | n/a | n/a | -SEK 140m |
Feb 29 2024 | n/a | n/a | -SEK 120m |
Nov 30 2023 | n/a | n/a | -SEK 116m |
Aug 31 2023 | SEK 3m | SEK 2m | -SEK 116m |
May 31 2023 | n/a | n/a | -SEK 119m |
Feb 28 2023 | n/a | n/a | -SEK 115m |
Nov 30 2022 | n/a | n/a | -SEK 99m |
Aug 31 2022 | SEK 3m | SEK 2m | -SEK 104m |
May 31 2022 | n/a | n/a | -SEK 91m |
Feb 28 2022 | n/a | n/a | -SEK 106m |
Nov 30 2021 | n/a | n/a | -SEK 83m |
Aug 31 2021 | SEK 3m | SEK 2m | SEK 60m |
May 31 2021 | n/a | n/a | SEK 74m |
Feb 28 2021 | n/a | n/a | SEK 99m |
Nov 30 2020 | n/a | n/a | SEK 121m |
Aug 31 2020 | SEK 3m | SEK 2m | SEK 10m |
May 31 2020 | n/a | n/a | SEK 13m |
Feb 29 2020 | n/a | n/a | SEK 13m |
Nov 30 2019 | n/a | n/a | -SEK 35m |
Aug 31 2019 | SEK 2m | SEK 1m | -SEK 37m |
May 31 2019 | n/a | n/a | -SEK 38m |
Feb 28 2019 | n/a | n/a | -SEK 43m |
Nov 30 2018 | n/a | n/a | -SEK 42m |
Aug 31 2018 | SEK 2m | SEK 1m | -SEK 44m |
Compensation vs Market: Ulf's total compensation ($USD321.83K) is about average for companies of similar size in the Swedish market ($USD443.40K).
Compensation vs Earnings: Ulf's compensation has increased whilst the company is unprofitable.
CEO
Ulf Hannelius (49 yo)
8.8yrs
Tenure
SEK 3,431,000
Compensation
Mr. Ulf Hannelius, PhD, MBA, has been the Chief Executive Officer of Diamyd Medical AB (publ) since April 11, 2016 and serves as its President. Mr. Hannelius served as an Interim Chief Executive Officer at...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & President | 8.8yrs | SEK 3.43m | 0.27% SEK 4.5m | |
Chief Financial Officer | no data | no data | 0.14% SEK 2.3m | |
Chief Operating Officer | 2.7yrs | no data | 0.012% SEK 198.8k | |
Chief Scientific Officer | 7.4yrs | no data | no data | |
Chief Operating Officer of Manufacturing Site | 2.1yrs | no data | 0.0024% SEK 39.7k |
5.0yrs
Average Tenure
49yo
Average Age
Experienced Management: DMYD B's management team is seasoned and experienced (5 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Member of the Scientific Advisory Board | 29.1yrs | no data | no data | |
Member of the Scientific Advisory Board | 26.1yrs | no data | no data | |
Independent Chairman | 29.1yrs | SEK 1.09m | 3.78% SEK 62.5m | |
Chairman of Scientific Advisory Board & Independent Director | 28.1yrs | SEK 175.00k | 0.016% SEK 266.3k | |
Independent Director | 3.8yrs | SEK 125.00k | 0.0096% SEK 159.0k | |
Independent Vice Chairman | 13.1yrs | SEK 214.00k | 0.056% SEK 933.8k | |
Independent Director | 8.1yrs | SEK 138.00k | 0.00096% SEK 15.9k | |
Independent Director | 16.1yrs | SEK 164.00k | 1.31% SEK 21.7m | |
Independent Director | 1.9yrs | SEK 125.00k | 0.000010% SEK 165.5 | |
Member of Scientific Advisory Board | less than a year | no data | no data | |
Member of Scientific Advisory Board | less than a year | no data | no data |
13.1yrs
Average Tenure
63yo
Average Age
Experienced Board: DMYD B's board of directors are seasoned and experienced ( 13.1 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/20 11:02 |
End of Day Share Price | 2025/02/20 00:00 |
Earnings | 2024/11/30 |
Annual Earnings | 2024/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Diamyd Medical AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Ludvig Svensson | Penser Access |